Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00561912 · ClinicalTrials.gov registry record · Phase 2
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00561912: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00561912 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00561912, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Primary Objective: * To determine the progression-free survival (PFS) times for patients with advanced renal cell carcinoma (RCC) treated with decitabine and interferon alfa-2b. Secondary Objectives: * To determine the toxicity of the combination of decitabine and interferon alfa-2b at the proposed dose and schedule in patients with advanced RCC * To determine overall response by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for patients with advanced RCC treated with decitabine and interferon alfa-2b. * To determine the overall survival times for patients with advanced RCC treated with decitabine and interferon. * To study the effects of decitabine and interferon alfa-2b on DNA methylation and gene expression in patients' tumor and non-tumor tissues and their correlation with clinical outcomes. * To characterize the modulation of cellular immunity induced by the combination of decitabine and interferon alfa-2b in patients with advanced RCC and to correlate these results with clinical outcomes.
Interventions
- DRUG Decitabine
- DRUG Interferon Alfa-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00561912
The ClinicalTrials.gov registry entry for NCT00561912 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Decitabine is the first listed.
NCT00561912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00561912 about?
NCT00561912 is a clinical study titled "Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma". Primary Objective: * To determine the progression-free survival (PFS) times for patients with advanced renal cell carcinoma (RCC) treated with decitabine and interferon alfa-2b. Secondary Objectives: * To determine the toxicity of the combination of decitabine and interferon alfa-2b at the propos...
What is the current status of trial NCT00561912?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2007-10. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00561912?
The interventions under investigation include: Decitabine (DRUG), Interferon Alfa-2b (DRUG).
Who is sponsoring clinical trial NCT00561912?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.